GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting

-  Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites  -

-  GW will also unveil its new U.S. operating name, Greenwich Biosciences, Inc.   -

LONDON, Dec. 01, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces results from two completed Epidiolex® (cannabidiol or CBD) Phase 3 trials, one in Lennox-Gastaut syndrome (LGS) and one in Dravet syndrome (DS), will be presented at the American Epilepsy Society (AES) Annual Meeting, December 2-6, 2016, in Houston, Texas. 

More than a dozen independent reports from the State-sponsored Epidiolex Expanded Access Program, as well as additional laboratory studies of CBD, scientific updates, and an overview of the legal and regulatory climate for cannabinoids will also be presented during the meeting.  For the first time, company-sponsored activities will be conducted under Greenwich Biosciences, Inc., GW's new name for its operating unit in the United States.

"We are very excited to share these data from our Phase 3 programs with the epilepsy community.  These presentations are the culmination of intensive effort by the GW in-house team and more than 50 participating sites over the past two years, and reflect the courage and commitment of patients and their families.  We can now focus on the ultimate goal, which is to gain approval for Epidiolex and make this much-needed treatment available," said Justin Gover, GW's Chief Executive Officer.  "We have also reached an ideal moment to introduce our new U.S. identity, Greenwich Biosciences, which will be the face of our company to patients and their families, clinicians, and the general public in the United States."

If you liked this article you might like

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Snap-On, Teekay Shipping, FLIR Systems, GW Pharmaceuticals: 'Mad Money' Lightning Round

Time to Raise Some Cash: Cramer's 'Mad Money' Recap (Tuesday 8/1/17)